DOI: 10.1016/j.dib.2019.104787; PMCID: PMC6880089
Here we present new and original data on the endogenous conversion of tyrosol (Tyr) into hydroxytyrosol (OHTyr) in humans and its effects on the cardiovascular system. A randomized, crossover, controlled clinical trial was performed with individuals at cardiovascular risk (n = 33). They received white wine (WW) (females 1, males 2 standard drinks/day), WW plus Tyr capsules (WW + Tyr) (25mg Tyr capsule, one per WW drink), and water (control) ad libitum. Intervention periods were of 4 weeks preceded by three-week wash-out periods. We assessed the conversion of Tyr to OHTyr, its interaction with a polygenic activity score (PAS) from CYP2A6 and CYP2D6 genotypes, and the effects on cardiovascular risk markers. For further details and experimental findings please refer to the article "Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial".
Boronat, A., Mateus, J., Soldevila-Domenech, N., Guerra, M., Rodríguez-Morató, J., Varon, C., Muñoz, D., Barbosa, F., Morales, J., Gaedigk, A., Langohr, K., Covas, M., Pérez-Mañá, C., Fitó, M., Tyndale, R. F., de la Torre, R. Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans. Data Brief 27, 104787-104787 (2019).